Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Interest & Investment Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Interest & Investment Income for 4 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 51.44% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a 34.59% decrease, with the full-year FY2024 number at $13.0 million, up 2.6% from a year prior.
  • Interest & Investment Income was $1.6 million for Q3 2025 at Century Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.6 million in Q2 2024 to a low of $1.4 million in Q3 2022.
  • A 4-year average of $2.8 million and a median of $3.0 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 147.23% in 2023, then plummeted 51.44% in 2025.
  • Century Therapeutics' Interest & Investment Income stood at $1.4 million in 2022, then surged by 148.94% to $3.5 million in 2023, then decreased by 17.92% to $2.9 million in 2024, then plummeted by 44.29% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Interest & Investment Income are $1.6 million (Q3 2025), $2.0 million (Q2 2025), and $2.4 million (Q1 2025).